Trial: 201810037

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma
(HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Phase

II

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx; Unknown Sites

Learn more about this study at: clinicaltrials.gov